BIOGEN INC. is 14.6x more valuable than ADMA BIOLOGICS, INC. by market capitalization ($28.68 B vs $1.97 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ADMA | BIIB |
|---|---|---|
| Market cap | $1.97 B | $28.68 B |
| US-listed rank | #2111 | #476 |
| Revenue (latest FY) | $510.17M | $9.89B |
| Net income (latest FY) | $146.93M | $1.29B |
| Net margin | 28.8% | 13.1% |
| P/E (trailing FY) | 13.4 | 22.2 |
| SEC filings | 988 | 2,690 |
BIOGEN INC. is 14.6x more valuable than ADMA BIOLOGICS, INC. by market capitalization ($28.68 B vs $1.97 B).
In their latest fiscal years, ADMA BIOLOGICS, INC. reported $510.17M in revenue while BIOGEN INC. reported $9.89B.
Full pages: ADMA BIOLOGICS, INC. and BIOGEN INC., or browse the full rankings.